ArticleUnited European gastroenterology journal2024

Atezolizumab and bevacizumab for non-resectable or metastatic combined hepatocellular-cholangiocarcinoma: A multicentric retrospective study.

Elia Gigante et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.